Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)

被引：0
|
作者：
Merriman, Joseph
Parikh, Kinjal
Tantravahi, Srinivas Kiran
Straubhar, Alli M.
Agarwal, Archana M.
Sendilnathan, Arun
Van Atta, Joan
Batten, Julia A.
Grossmann, Kenneth F.
Samlowski, Wolfram E.
Stenehjem, David D.
Agarwal, Neeraj
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Dept Pathol & ARUP Labs, Salt Lake City, UT USA
[3] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[4] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4577
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Correlation of tumor programmed death ligand-1 (PD-Ll) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in metastatic clear cell renal cell carcinoma (mccRCC).
    Gill, David
    Agarwal, Neeraj
    Stenehjem, David
    Agarwa, Archana F.
    Salama, Mohamad
    Merriman, Joseph
    Freeman, Gordon J.
    Choueiri, Toni K.
    Signoretti, Sabina
    BJU INTERNATIONAL, 2015, 116 : 8 - 9
  • [22] High-dose interleukin-2 in metastatic disease: Renal cell carcinoma and melanoma
    Dutcher, J
    ONCOLOGY-NEW YORK, 2002, 16 (11): : 3 - 3
  • [23] Immune checkpoint inhibitors (ICI) in clear cell renal cell carcinoma (ccRCC) following high-dose interleukin-2 (IL-2)
    Elias, Roy
    Bowman, Isaac Alexander
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Phase 2 Trial of High-Dose Interleukin-2 (IL-2) and Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)-Interim Analysis of i-SAbR IL-2 Trial
    Ishihara, D.
    Louder, K.
    Akter, M.
    Ahn, C.
    Margulis, V.
    Arriaga, Y.
    Courtney, K.
    Timmerman, R. D.
    Brugarolas, J.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S96 - S97
  • [25] A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
    Garcia, J. A.
    Rini, B. I.
    Mekhail, T.
    Triozzi, P.
    Elson, P.
    Nemec, C.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in clear cell metastatic renal cell carcinoma (ccmRCC).
    Crispin, Hilda
    Agarwal, Archana M.
    Salama, Mohamed E.
    Tantravahi, Srinivas Kiran
    Merriman, Joseph
    Straubhar, Alli M.
    Poole, Austin
    Nussenzvelg, Roberto
    Stenehjem, David I.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] The application of high-dose interleukin-2 for metastatic renal cell carcinoma
    McDermott, David F.
    MEDICAL ONCOLOGY, 2009, 26 : 13 - 17
  • [28] High-dose interleukin-2 in metastatic renal cell carcinoma - Reply
    McDermott, DF
    Atkins, MB
    Regan, MM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6798 - 6799
  • [29] The application of high-dose interleukin-2 for metastatic renal cell carcinoma
    David F. McDermott
    Medical Oncology, 2009, 26 : 13 - 17
  • [30] Long-term disease- free survival (DFS) of metastatic melanoma (mM) and renal cell cancer (mRCC) patients following high-dose interleukin-2 (HD IL2)
    Clark, Joseph
    Curti, Brendan
    Davis, Elizabeth
    Kaufman, Howard
    Amin, Asim
    Alva, Ajjai
    Logan, Theodore
    Hauke, Ralph
    Miletello, Gerald
    Vaishampayan, Ulka
    Johnson, Douglas
    White, Richard
    Wiernik, Peter
    Dutcher, Janice
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345